Market Research Logo

Oncology Drugs Market Global Report 2017 Including: Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Non-Small Cell Lung Cancer , Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, B

Oncology Drugs Market Global Report 2017 Including: Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Non-Small Cell Lung Cancer , Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Cancer, Cervical Cancer, Blood Cancer, Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)Covering: F. Hoffmann-La Roche Ltd, Novartis AG, Celgene, Johnson & Johnson, and Bristol-Myers Squibb Company

Increase in usage of biotechnological technologies in the development of anticancer drugs such as immunotherapies or monoclonal antibodies, adoptive-cell therapies, and new vaccines is an emerging trend in this market. Major competitors such as Roche, Eli Lilly, Genentech, Pfizer, and Biogen Idec are focusing on the R&D of new technologies such as next generation sequencing to develop MABs that are used for the development of chronic diseases such as cancer and other chronic diseases.

The Oncology Drugs Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global oncology drugs sector.

Reasons to Purchase

  • Outperform competitors using accurate up to date demand-side dynamics information.
  • Identify growth segments for investment.
  • Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
  • Create regional and country strategies on the basis of local data and analysis.
  • Stay abreast of the latest customer and market research findings
  • Benchmark performance against key competitors.
  • Develop strategies based on likely future developments.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Gain a global perspective on the development of the market.
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:

Where is the largest and fastest growing market for the oncology drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oncology drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical drugs market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
  • The oncology drugs market section of the report gives context. It compares the oncology drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The Oncology Drugs Indicators Comparison.
  • The industry metrics section looks at critical drivers including patient numbers (epidemiology) hospital beds and specialist physicians while the macro-economic section looks at the market in relation to the overall economy.
Scope

Markets Covered: Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Non-Small Cell Lung Cancer , Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Cancer, Cervical Cancer, Blood Cancer, Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)

Companies Mentioned: F. Hoffmann-La Roche Ltd, Novartis AG, Celgene, Johnson & Johnson, and Bristol-Myers Squibb Company

Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa

Time series: Five years historic and forecast.

Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Oncology Drugs Indicators Comparison.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.


1. Oncology Drugs Market Characteristics
2. Oncology Drugs Market Size And Growth
2.1. Historic Market Growth
2.1.1. Drivers Of The Market
2.1.2. Restraints On The Market
2.2. Forecast Market Growth
2.2.1. Drivers Of The Market
2.2.2. Restraints On The Market
3. Pestle Analysis
3.1. Political
3.2. Economic
3.3. Social
3.4. Technological
3.5. Legal
3.6. Environmental
4. Oncology Drugs Market Customer Information
5. Oncology Drugs Market Segmentation
5.1. Global Oncology Drugs Market, 2016, By Segment
Lung Cancer
Pancreatic Cancer
Breast Cancer
Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Gastric Cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Brain Tumor
Thyroid Cancer
Skin Cancer
Bladder Cancer
Cervical Cancer
Blood Cancer
Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
5.2. Global Oncology Drugs Market, 2012 - 2020, Historic And Forecast, By Segment
5.3 Global Oncology Drugs Market Trends And Strategies
6. Oncology Drugs Market Regional And Country Analysis
6.1. Global Oncology Drugs Market, 2016, By Region
6.2. Global Oncology Drugs Market, 2012 - 2020, Historic And Forecast, By Region
6.3. Oncology Drugs Market, 2016, By Country
6.4. Oncology Drugs Market, 2012 - 2020, Historic And Forecast, By Country
6.5. Global Pharmaceutical Market Segments, 2016, By Region
6.6. Global Pharmaceutical Drugs Market Segments, 2016, By Region
6.7. Global Pharmaceutical Market Segments, 2016, By Country
6.8. Global Pharmaceutical Drugs Market Segments, 2016, By Country
7. Global Oncology Drugs Market Comparison With Macro Economic Factors
7.1. Oncology Drugs Market Size, Percentage Of GDP, Global
7.2. Per Capita Average Oncology Drugs Expenditure, Global
8. Oncology Drugs Market Comparison With Macro Economic Factors Across Countries
8.1. Oncology Drugs Market Size, Percentage Of GDP, By Country
8.2. Per Capita Average Oncology Drugs Expenditure, By Country
9. Oncology Drugs Market Comparison With Industry Metrics
9.1. Global Number Of Pharmacists, 2016, By Country
9.2. Global Oncology Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country
9.3. Global Number Of Pharma Enterprises, 2016, By Country
9.4. Global Oncology Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country
9.5. Global Average Spending On R&D/Product Development, 2016, By Country
9.6. Global Oncology Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country
9.7. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country
9.8. Global Oncology Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country
9.9. Prevalent Cases Of Cancer, 2016, By Country
10. Asia-Pacific Oncology Drugs Market
10.1.1. Asia-Pacific Oncology Drugs Market Overview
10.1.2. Asia-Pacific Oncology Drugs Historic Market, 2012 - 2016
10.1.3. Asia-Pacific Oncology Drugs Forecast Market, 2016 - 2020
10.1.4. Asia-Pacific Oncology Drugs Market, 2016, By Segment
Lung Cancer
Pancreatic Cancer
Breast Cancer
Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Gastric Cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Brain Tumor
Thyroid Cancer
Skin Cancer
Bladder Cancer
Cervical Cancer
Blood Cancer
Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
10.2. Asia-Pacific Oncology Drugs Market: Country Analysis
10.3. China Oncology Drugs Market
10.3.1. China Oncology Drugs Market Overview
10.3.2. China Oncology Drugs Historic Market, 2012 - 2016
10.3.3. China Oncology Drugs Forecast Market, 2016 - 2020
10.3.4. China Oncology Drugs Market, 2016, By Segment
Lung Cancer
Pancreatic Cancer
Breast Cancer
Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Gastric Cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Brain Tumor
Thyroid Cancer
Skin Cancer
Bladder Cancer
Cervical Cancer
Blood Cancer
Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
10.3.5. China Oncology Drugs Percentage Of GDP, 2012 - 2020
10.3.6. China Per Capita Average Oncology Drugs Expenditure, 2012 - 2020
10.4. India Oncology Drugs Market
10.4.1. India Oncology Drugs Market Overview
10.4.2. India Oncology Drugs Historic Market, 2012 - 2016
10.4.3. India Oncology Drugs Forecast Market, 2016 - 2020
10.4.4. India Oncology Drugs Market, 2016, By Segment
Lung Cancer
Pancreatic Cancer
Breast Cancer
Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Gastric Cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Brain Tumor
Thyroid Cancer
Skin Cancer
Bladder Cancer
Cervical Cancer
Blood Cancer
Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
10.4.5. India Oncology Drugs Percentage Of GDP, 2012 - 2020
10.4.6. India Per Capita Average Oncology Drugs Expenditure, 2012 - 2020
10.5. Japan Oncology Drugs Market
10.5.1. Japan Oncology Drugs Market Overview
10.5.2. Japan Oncology Drugs Historic Market, 2012 - 2016
10.5.3. Japan Oncology Drugs Forecast Market, 2016 - 2020
10.5.4. Japan Oncology Drugs Market, 2016, By Segment
Lung Cancer
Pancreatic Cancer
Breast Cancer
Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Gastric Cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Brain Tumor
Thyroid Cancer
Skin Cancer
Bladder Cancer
Cervical Cancer
Blood Cancer
Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
10.5.5. Japan Oncology Drugs Percentage Of GDP, 2012 - 2020
10.5.6. Japan Per Capita Average Oncology Drugs Expenditure, 2012 - 2020
10.6. Australia Oncology Drugs Market
10.6.1. Australia Oncology Drugs Historic Market, 2012 - 2016
10.6.2. Australia Oncology Drugs Forecast Market, 2016 - 2020
10.6.3. Australia Oncology Drugs Market, 2016, By Segment
Lung Cancer
Pancreatic Cancer
Breast Cancer
Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Gastric Cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Brain Tumor
Thyroid Cancer
Skin Cancer
Bladder Cancer
Cervical Cancer
Blood Cancer
Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
10.6.4. Australia Oncology Drugs Percentage Of GDP, 2012 - 2020
10.6.5. Australia Per Capita Average Oncology Drugs Expenditure, 2012 - 2020
11. Western Europe Oncology Drugs Market
11.1.1. Western Europe Oncology Drugs Market Overview
11.1.2. Western Europe Oncology Drugs Historic Market, 2012 - 2016
11.1.3. Western Europe Oncology Drugs Forecast Market, 2016 - 2020
11.1.4. Western Europe Oncology Drugs Market, 2016, By Segment
Lung Cancer
Lung Cancer
Pancreatic Cancer
Breast Cancer
Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Gastric Cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Brain Tumor
Thyroid Cancer
Skin Cancer
Bladder Cancer
Cervical Cancer
Blood Cancer
Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
11.2. Western Europe Oncology Drugs Market: Country Analysis
11.3. UK Oncology Drugs Market
11.3.1. UK Oncology Drugs Market Overview
11.3.2. UK Oncology Drugs Historic Market, 2012 - 2016
11.3.3. UK Oncology Drugs Forecast Market, 2016 - 2020
11.3.4. UK Oncology Drugs Market, 2016, By Segment
Lung Cancer
Pancreatic Cancer
Breast Cancer
Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Gastric Cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Brain Tumor
Thyroid Cancer
Skin Cancer
Bladder Cancer
Cervical Cancer
Blood Cancer
Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
11.3.5. UK Oncology Drugs Percentage Of GDP, 2012 - 2020
11.3.6. UK Per Capita Average Oncology Drugs Expenditure, 2012 - 2020
11.4. Germany Oncology Drugs Market
11.4.1. Germany Oncology Drugs Historic Market, 2012 - 2016
11.4.2. Germany Oncology Drugs Forecast Market, 2016 - 2020
11.4.3. Germany Oncology Drugs Market, 2016, By Segment
Lung Cancer
Pancreatic Cancer
Breast Cancer
Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Gastric Cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Brain Tumor
Thyroid Cancer
Skin Cancer
Bladder Cancer
Cervical Cancer
Blood Cancer
Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
11.4.4 Germany Oncology Drugs Percentage Of GDP, 2012 - 2020
11.4.5 Germany Per Capita Average Oncology Drugs Expenditure, 2012 - 2020
11.5 France Oncology Drugs Market
11.5.1 France Oncology Drugs Historic Market, 2012 - 2016
11.5.2 France Oncology Drugs Forecast Market, 2016 - 2020
11.5.3 France Oncology Drugs Market, 2016, By Segment
Lung Cancer
Pancreatic Cancer
Breast Cancer
Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Gastric Cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Brain Tumor
Thyroid Cancer
Skin Cancer
Bladder Cancer
Cervical Cancer
Blood Cancer
Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
11.5.4 France Oncology Drugs Percentage Of GDP, 2012 - 2020
11.5.5 France Per Capita Average Oncology Drugs Expenditure, 2012 - 2020
11.6. Italy Oncology Drugs Market
11.6.2. Italy Oncology Drugs Forecast Market, 2016 - 2020
11.6.3. Italy Oncology Drugs Market, 2016, By Segment
Lung Cancer
Pancreatic Cancer
Breast Cancer
Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Gastric Cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Brain Tumor
Thyroid Cancer
Skin Cancer
Bladder Cancer
Cervical Cancer
Blood Cancer
Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
11.6.4. Italy Oncology Drugs Percentage Of GDP, 2012 - 2020
11.6.5. Italy Per Capita Average Oncology Drugs Expenditure, 2012 - 2020
11.7. Spain Oncology Drugs Market
11.7.1. Spain Oncology Drugs Historic Market, 2012 - 2016
11.7.2. Spain Oncology Drugs Forecast Market, 2016 - 2020
11.7.3. Spain Oncology Drugs Market, 2016, By Segment
Lung Cancer
Pancreatic Cancer
Breast Cancer
Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Gastric Cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Brain Tumor
Thyroid Cancer
Skin Cancer
Bladder Cancer
Cervical Cancer
Blood Cancer
Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
11.7.4. Spain Oncology Drugs Percentage Of GDP, 2012 - 2020
11.7.5. Spain Per Capita Average Oncology Drugs Expenditure, 2012 - 2020
12. Eastern Europe Oncology Drugs Market
12.1.1. Eastern Europe Oncology Drugs Market Overview
12.1.2. Eastern Europe Oncology Drugs Historic Market, 2012 - 2016
12.1.3. Eastern Europe Oncology Drugs Forecast Market, 2016 - 2020
12.1.4 Eastern Europe Oncology Drugs Market, 2016, By Segment
Lung Cancer
Pancreatic Cancer
Breast Cancer
Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Gastric Cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Brain Tumor
Thyroid Cancer
Skin Cancer
Bladder Cancer
Cervical Cancer
Blood Cancer
Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
12.2. Eastern Europe Oncology Drugs Market: Country Analysis
12.3. Russia Oncology Drugs Market
12.3.1. Russia Oncology Drugs Historic Market, 2012 - 2016
12.3.2. Russia Oncology Drugs Forecast Market, 2016 - 2020
12.3.3. Russia Oncology Drugs Market, 2016, By Segment
Lung Cancer
Pancreatic Cancer
Breast Cancer
Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Gastric Cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Brain Tumor
Thyroid Cancer
Skin Cancer
Bladder Cancer
Cervical Cancer
Blood Cancer
Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
12.3.4. Russia Oncology Drugs Percentage Of GDP, 2012 - 2020
12.3.5. Russia Per Capita Average Oncology Drugs Expenditure, 2012 - 2020
13. North America Oncology Drugs Market
13.1.1. North America Oncology Drugs Market Overview
13.1.2. North America Oncology Drugs Historic Market, 2012 - 2016
13.1.3. North America Oncology Drugs Forecast Market, 2016 - 2020
13.1.4. North America Oncology Drugs Market, 2016, By Segment
Lung Cancer
Pancreatic Cancer
Breast Cancer
Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Gastric Cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Brain Tumor
Thyroid Cancer
Skin Cancer
Bladder Cancer
Cervical Cancer
Blood Cancer
Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
13.2. North America Oncology Drugs Market: Country Analysis
13.3. USA Oncology Drugs Market
13.3.1. USA Oncology Drugs Historic Market, 2012 - 2016
13.3.2. USA Oncology Drugs Forecast Market, 2016 - 2020
13.3.3 USA Oncology Drugs Market, 2016, By Segment
Lung Cancer
Pancreatic Cancer
Breast Cancer
Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Gastric Cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Brain Tumor
Thyroid Cancer
Skin Cancer
Bladder Cancer
Cervical Cancer
Blood Cancer
Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
13.3.4. USA Oncology Drugs Percentage Of GDP, 2012 - 2020
13.3.5. USA Per Capita Average Oncology Drugs Expenditure, 2012 - 2020
14. South America Oncology Drugs Market
14.1.1. South America Oncology Drugs Market Overview
14.1.2. South America Oncology Drugs Historic Market, 2012 - 2016
14.1.3. South America Oncology Drugs Forecast Market, 2016 - 2020
14.1.4. South America Oncology Drugs Market, 2016, By Segment
Lung Cancer
Pancreatic Cancer
Breast Cancer
Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Gastric Cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Brain Tumor
Thyroid Cancer
Skin Cancer
Bladder Cancer
Cervical Cancer
Blood Cancer
Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
14.2. South America Oncology Drugs Market: Country Analysis
14.3. Brazil Oncology Drugs Market
14.3.1. Brazil Oncology Drugs Historic Market, 2012 - 2016
14.3.2. Brazil Oncology Drugs Forecast Market, 2016 - 2020
14.3.3. Brazil Oncology Drugs Market, 2016, By Segment
Lung Cancer
Pancreatic Cancer
Breast Cancer
Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Gastric Cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Brain Tumor
Thyroid Cancer
Skin Cancer
Bladder Cancer
Cervical Cancer
Blood Cancer
Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
14.3.4. Brazil Oncology Drugs Percentage Of GDP, 2012 - 2020
14.3.5. Brazil Per Capita Average Oncology Drugs Expenditure, 2012 - 2020
15. Middle East Oncology Drugs Market
15.1.1. Middle East Oncology Drugs Market Overview
15.1.2. Middle East Oncology Drugs Historic Market, 2012 - 2016
15.1.3. Middle East Oncology Drugs Forecast Market, 2016 - 2020
15.1.4. Middle East Oncology Drugs Market, 2016, By Segment
Lung Cancer
Pancreatic Cancer
Breast Cancer
Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Gastric Cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Brain Tumor
Thyroid Cancer
Skin Cancer
Bladder Cancer
Cervical Cancer
Blood Cancer
Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
16. Africa Oncology Drugs Market
16.1.1. Africa Oncology Drugs Market Overview
16.1.2. Africa Oncology Drugs Historic Market, 2012 - 2016
16.1.3. Africa Oncology Drugs Forecast Market, 2016 - 2020
16.1.4. Africa Oncology Drugs Market, 2016, By Segment
Lung Cancer
Pancreatic Cancer
Breast Cancer
Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Gastric Cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Brain Tumor
Thyroid Cancer
Skin Cancer
Bladder Cancer
Cervical Cancer
Blood Cancer
Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
17. Oncology Drugs Market Competitive Landscape
17.1. Company Profiles
17.2. F. Hoffmann-La Roche Ltd
17.2.1. Overview
17.2.2. Products And Services
17.2.3. Strategy
17.2.4. Financial Performance
17.3. Novartis Ag
17.3.1. Overview
17.3.2. Products And Services
17.3.3. Strategy
17.3.4. Financial Performance
17.4. Celgene
17.4.1. Overview
17.4.2. Products And Services
17.4.3. Strategy
17.4.4. Financial Performance
17.5. Johnson & Johnson
17.5.1. Overview
17.5.2. Products And Services
17.5.3. Strategy
17.5.4. Financial Performance
17.6. Bristol-Myers Squibb Company 17.6.1. Overview
17.6.2. Products And Services
17.6.3. Strategy
17.6.4. Financial Performance
18. Key Mergers And Acquisitions In The Oncology Drugs Market
19. Market Background: Pharmaceutical Drugs Market
19.1.1. Pharmaceutical Drugs Market Characteristics
19.1.2. Pharmaceutical Drugs Market Historic Growth
19.1.2.1. Drivers Of The Market
19.1.2.2. Restraints Of The Market
19.1.3. Pharmaceutical Drugs Market Forecast Growth
19.1.3.1. Drivers Of The Market
19.1.3.2. Restraints Of The Market
19.1.4. Pharmaceutical Drugs Trends And Strategies
19.2. Pharmaceutical Drugs Market Regional And Country Analysis
19.2.1. Global Pharmaceutical Drugs Market, 2016, By Region
19.2.2. Global Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Region
19.2.3. Pharmaceutical Drugs Market, 2016, By Country
19.2.4. Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Country
19.2.5. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment
19.2.6. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment
19.3. Global Pharmaceutical Drugs Market Comparison With Macro Economic Factors
19.3.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, Global
19.3.2. Per Capita Average Pharmaceutical Drugs Expenditure, Global
19.4. Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries
19.4.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country
19.4.2. Per Capita Average Pharmaceutical Drugs Expenditure, By Country
19.5. Key Mergers And Acquisitions In The Pharmaceutical Drugs Market
20. Pharmaceuticals Industry Financial Margins
21. Appendix
21.1. NAICS Definitions Of Industry Covered In This Report
21.2. Abbreviations
21.3. Currencies
21.4. Research Inquiries
21.5. The Business Research Company
21.6. Copyright And Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report